Corbus Pharma

Forecast & Rating10 analysts currently cover Corbus Pharma, with about 100.0% giving a positive rating — meaning they expect the stock to rise. The average price target is $34.03, about 391.7% upside from the current price of $6.92. Price targets range from $17.25 to $48.00 — a wide spread, showing clear disagreement over just how much Corbus Pharma can rise. Historically, about 38.9% of past price targets were eventually met, which adds credibility. For you, this means most professionals who study Corbus Pharma closely still see room for the stock to rise. Data as of Sep 14, 2026; for reference only and not investment advice.